PHASE 1

October 2024

• All the links have been checked and are working properly.

• ​There were no changes to the number of clinical trials since the previous update.

• XB010 (5T4-MMAE ADC) was added to the Phase 1 table. 
   

August 2024

• All the links have been checked and are working properly.

• Griffthisin (GRFT): although there are no active clinical trials,  Dr. O’Keefe sent the following message by email (8/2/2024): “The GRFT Phase I trials have been completed. A manuscript detailing the results of the Phase 1 trial of the intranasal formulation of Q-GRFT (the oxidation resistant analog of GRFT) for SARS-CoV-2 prevention is in preparation. On the HIV front, the Population Council is still moving forward with wild type GRFT and carrageenan in a fast-dissolving insert formulation for use as a topical microbicide. Their successful Phase 1 results with a GRFT/carrageenan gel were published in 2023. The Population Council were funded by NIAID to continue work on a newer fast-dissolving insert formulation of a GRFT-based microbicide”.

• PM54: the following link was added: Abstract 1880: Ecubectedin and PM54 demonstrate antitumor activity in patient-derived xenograft models of soft tissue sarcoma | Cancer Research | American Association for Cancer Research (aacrjournals.org)

• PM534: the following link was added: PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin | Journal of Medicinal Chemistry (acs.org)

​

June 2024

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly.

  • ARX-517: clinical trials have been consolidated from Phase 2 to Phase 1.

  • BT5528 was consolidated from Phase 1 to Phase 2. 

  • Griffthisin: no longer has clinical trials.

April 2024

• ARX-788: clinical trials have been consolidated from Phase 1 to Phase 3.

• STRO-002: clinical trials have been consolidated from Phase 1 to Phase 2.

• FOR-46: clinical trials have been consolidated from Phase 1 to Phase 2

• ARX-517: clinical trials have been consolidated from Phase 1 to Phase 2

• STI-6129: clinical trials have been consolidated from Phase 1 to Phase 2

• SGN-B6A: clinical trials have been consolidated from Phase 1 to Phase 3

• RC-88: clinical trials have been consolidated from Phase 1 to Phase 2

• ARX-517: clinical trials have been consolidated from Phase 1 to Phase 2

• Upifitamab rilsodotin (XMT-1536): clinical trials have been consolidated from Phase 1 to Phase 2

• MRG003: clinical trials have been consolidated from Phase 1 to Phase 3.

• A-166: clinical trials have been consolidated from Phase 1 to Phase 2

• BT8009: clinical trials have been consolidated from Phase 2 to Phase 3.

• ALT-P7: Removed from Phase I. No longer has active clinical trials.

• Farletuzumab ecteribulin (MORAb-202): clinical trials have been consolidated from Phase 1 to Phase 2

• EBC-129: a new row for this new Phase 1 study was added

​

February 2024

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly.

  • MRG003: The link for U.S. Clinical trials and Chinese clinical trials were updated.

  • ALTP-7: although one clinical trial is listed on clinicaltrials.gov  as completed, it remains on the manufacturer website.

  • SGN-B6A: Pfizer has completed the acquisition of Seagen, so the link is to Pfizer’s website.

  • SGN-CD228A: has been removed as the only clinical trial listed is terminated and it no longer is present in the on the Seagen/Pfizer clinical pipeline.

  • A-166: Link for U.S. clinical trials was updated.

  • Upifitamab rilsodotin (XMT-1536): Clinical trials in U.S shows 1 trial that is “active, not recruiting”. Most recently the FDA paused Upifitamab rilsodotin trials: FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer (cancernetwork.com)

  • ARX-517: a new row was added.

  • Leucettinib-21: a new row was added.

December 2023

• All the links have been checked and are working properly. 

• The number of current clinical trials was updated accordingly. 

• MRG003: Link for Chinese clinical trials was updated. 

• A-166: Link for U.S. clinical trials was updated. 

• Upifitamab rilsodotin (XMT-1536): Clinical trials in U.S shows 1 trial that is “active, not recruiting”. 

• Most recently the FDA paused Upifitamab rilsodotin trials: FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer (cancernetwork.com)

• ARX-517: a new row was added.

​

October 2023

• All the links have been checked and are properly working. 

• BT8009 target was updated to Nectin-4 (PVRL4).

• Name of MORAb202 was updated to Farleztuzumab ecteribulin and the chemical class updated to ADC (Ecteribulin).

• New row added for compounds PM54 and PM534

• Removed indication for HIV for griffithsin, due to the fact that the clinical trial for this indication was terminated. 

• The number of current clinical trials was updated accordingly. 

August 2023

• All the links have been checked and are properly working. 

​

June 2023

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly.

• New links were added for the “Compound Name” for: STRO-002, Cofetuzumab pelidotin, and STI-6129.

​

April 2023

• Link for Cofetuzumab pelidotin’s “Company/Institution” has been updated with AbbVie's current pipeline webpage. All other links have been checked and are properly working.

• The number of current clinical trials was updated accordingly.

Points discussed during meeting:

• PF-06804103: This compound has no more active clinical trials; it is not found in the Pipeline on Pfizer’s website anymore either. It was decided to remove this compound in the Phase 1 page.

• SGN-CD228A: This compound’s Phase 1 study is “terminated”; however, it is still on the Pipeline under phase 1 on Seagen’s website. It was decided we should keep this compound in the Phase 1 page for some months.

​

February 2023

• All the links have been checked and were working properly. 

• The number of current clinical trials was updated accordingly.

• Link has been updated to show the company's pipeline page for A-166. 

• Compound name for MorAb-202 has been updated to Farletuzumab Ecteribulin (MorAb-202). 

• New compound, EBC-129, has been added. 
   

December 2022 

All the links have been checked and were working properly. The number of clinical trials in Phase 1 is currently reflected on the website. Recent updates to phase 1 clinical trials include compounds completing phase 1, progressing to phase 2, and phase 3. 

• ARX-788: has six trials in progress: 1 phase 1 trial, 5 phase 2 trials, and 1 phase 3 trial.   

• XMT-153:  named upifitamab rilsodotin, has 2 phase 1 trials, 1 phase 2 trial and 1 phase 3 trial.  

• MORAb-202: has 3 phase 2 trials, and 1 phase 1 trial.   

• MRG003: has 5 phase 2 trials, and 1 phase 1 trial.  

• RC-88: has 1 phase 2 trial, and 2 phase 1 trials.  

• STI-6129:  3 Phase 2 trials, and 5 phase 1 trials.   

​

September 2022

• During September copyright notices were posted on the top and bottom of this page. Date of the last update has been edited.  

• ARX-788 has 6 US clinical trials ( https://clinicaltrials.gov/ct2/results?cond=ARX788&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=), and has been added to the Phase 3 webpage.

• XMT-1536 (upifitamab rilsodotin)  has a US Active Phase 3 trial ( https://clinicaltrials.gov/ct2/show/NCT05329545?recrs=abdf&cond=XMT-1536&draw=2&rank=2) has been added to the Phase 3 webpage.  

• MORab-202 (Farletuzumab  Ecteribulin) has a US Active Phase 2 trial (https://www.clinicaltrials.gov/ct2/show/NCT04300556?recrs=abdf&cond=MORAb-202&draw=2&rank=2) and has been added to the Phase 2 webpage.

• MRG003 has 5 US Active Phase 2 trials (https://clinicaltrials.gov/ct2/resultscond=mrg003&term=&cntry=&state=&city=&dist=&Search=Search) and has been added to the Phase 2 webpage.

• A-166 has 2 US Active Phase 2 trials (https://clinicaltrials.gov/ct2/show/NCT05346328?cond=A-166&draw=2&rank=3) and has been added to the Phase 2 webpage.